about
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapyOpioids for the management of breakthrough pain in cancer patientsParasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapyOpioids for the palliation of breathlessness in terminal illness.A systematic review of the use of opioids in the management of dyspnoea.Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipationDefinitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review.Alternative forms of hydration in patients with cancer in the last days of life: study protocol for a randomised controlled trial.Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.The management of breakthrough cancer pain.A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.Breakthrough cancer pain.Observational study of sleep disturbances in advanced cancer.Accuracy of a Diagnostic Algorithm to Diagnose Breakthrough Cancer Pain as Compared With Clinical Assessment.The management of xerostomia: a review.Paraneoplastic Raynaud's phenomenon--good palliation after a multidisciplinary approach.Re: Sodium valproate in cancer-related neuropathic pain.Opioid-related musical hallucinations.Stercoral Perforation of the Colon: A Potentially Fatal Complication of Opioid-Induced Constipation.Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.Breakthrough cancer pain.Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer.Oral transmucosal fentanyl citrate and xerostomia.Susceptibility to Melaleuca alternifolia (tea tree) oil of yeasts isolated from the mouths of patients with advanced cancer.The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain.A cluster randomised feasibility trial of clinically assisted hydration in cancer patients in the last days of life.Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.Letter to the Editor re 'Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer (BMJ Support Palliat Care 2016;6:344-52)'.Disparities Between Clinician and Patient Perception of Breakthrough Pain Control.Breakthrough cancer pain: the role of the nurse.Oral yeast carriage in patients with advanced cancer.Incorrect Use of the English Language Term "Episodic".Palliative medicine must accept responsibility for end of life care.Methotrimeprazine and UV lightTransdermal fentanyl and the opioid withdrawal syndromeThalassaemic osteoarthropathy treated with radiotherapyA comparison of artificial saliva and pilocarpine in radiation-induced xerostomiaTrigeminal neuralgia managed by a change in lifestyleA comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer
P50
Q24186632-C7433C6C-9DB0-41CE-9E53-16E0F6EC85D8Q24202962-27729F27-D3C0-42B8-9D96-381FE6327A46Q24244387-6163D732-CD81-44F6-B8B0-C0BFA991A238Q30759111-BC6317B8-5BCD-48CD-849A-E2FA8F6B0251Q34156523-DEA84DD4-AE7F-48FB-B60F-C54CBF0F6174Q35174654-0F8BA18A-1392-4D99-A97A-F0CE255E50C2Q35377907-FDFB93A4-A4BF-4D1B-AA2C-556AFD0BC765Q36165748-05DE2EB2-84C2-4D6C-9B2B-D9B9E1F410CAQ36459019-DD821874-A48F-4331-BB7F-308538AF4421Q37245357-499F7CD5-48D8-458A-9AF3-097CC50A0DEEQ37917548-0455D548-ACFA-4BC0-A783-06B7E83D52E9Q38131911-A6776152-AF56-4DF3-A1C2-5F38AB4AD3F6Q38206737-E5C37D2E-CD07-4905-B3AC-282CA0B23A8EQ38611205-3035FA51-8F8A-42FE-A42A-3C897E7836A2Q40888915-44DE68CA-1FA1-40E7-A6EB-4A0A06F38D53Q41614768-B7DACF0B-8912-448B-81CD-0B0402FFCF74Q43143912-3AEE3812-E7BD-41E5-8F0E-A47460728573Q43846940-DC8200AF-8D48-4442-8AB5-156012905952Q44348775-57F21055-B974-4361-ADB2-3F4E49DAA2D9Q44350556-6DE58377-FAF8-4855-BCD9-7EFC6515EE35Q44375313-472AE56D-6FE3-48A8-8EE2-46ED48F3FED8Q46228964-7DD0089A-8B7B-45EA-90BD-2BE7393CD6BEQ46699039-DB8672DD-FAFD-4BA5-8F13-28D44F738119Q46867241-335C08F5-34DE-4591-AD10-D6B079C0F531Q46952108-DECA70C3-BF9D-4232-8A61-F4836F970146Q47610975-4018F24D-DA35-45E8-8FE5-8812460B2FEEQ47654618-E1666C40-F662-4C87-9133-D54E270C6EE4Q47821345-C03B5221-68FB-4432-B2CA-7DEAD5C117A2Q48159216-BA4812F5-672A-40E8-B10F-B03924790742Q50894510-779A8E21-1021-458E-9231-7CFB85CE4DE4Q51099156-923EBF75-ECA8-4235-9DF8-7A59E0E386B3Q52043448-84E78971-3E9F-44A2-89A4-4BDFCEAEEF4DQ53937630-D268804E-AF64-4748-ADBF-35BF65A9C894Q54490367-184F7794-204E-416C-8BE5-A52D36E18FDDQ71559072-8EB62BC2-3C1E-4569-B8E3-BF0FA2103EF5Q71806647-A0973493-B5E1-4984-B3DA-EC54DB24049AQ72311548-13CAA50F-05C6-4084-A0B4-985EFCE859CEQ72728177-43BCE5E7-C7BC-4346-9EBA-4A2625D44B48Q73531536-9D79E10C-2C40-4270-B7F9-62A5B28DEEEDQ73906462-86E8E1E6-2D3A-4E84-B551-3AE94299970C
P50
description
researcher
@en
wetenschapper
@nl
name
Andrew N. Davies
@en
Davies AN
@nl
type
label
Andrew N. Davies
@en
Davies AN
@nl
altLabel
Davies AN
@en
prefLabel
Andrew N. Davies
@en
Davies AN
@nl
P106
P31
P496
0000-0003-4207-4799